A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma - PubMed (original) (raw)
Review
A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma
Tomohiro Funakoshi et al. Cancer Treat Rev. 2014 May.
Abstract
Background: Vascular endothelial growth factor (VEGF)-targeted therapy is the currently standard treatment for advanced and metastatic renal cell carcinoma (RCC). Multiple candidate predictive and prognostic biomarkers have been evaluated. We performed a systematic review and graded the available evidence on the biomarkers for VEGF-targeted therapy in RCC.
Methods: We conducted an independent review of PubMed and ASCO databases up to August 2013. Studies were included if biomarkers obtained from metastatic clear-cell RCC patients treated with the FDA-approved VEGF-targeted therapy were assessed for their correlation with clinical outcomes. We graded the studies and determined the Level-of-evidence for each biomarker using a previously published framework.
Results: A total of 50 articles were selected for this review. Seven studies assessed the predictive value of biomarkers using the archived specimens from randomized controlled trials. Five predictive biomarkers, such as VEGF, interleukin (IL)-6, hepatocyte growth factor (HGF), osteopontin, single nucleotide polymorphisms in IL-8, satisfied Level II evidence. IL-6 is the most corroborated predictive biomarker based on its consistent predictive value in two different trials. The prognostic value of biomarkers was assessed in 48 studies using the archived specimens from clinical trials, prospective and retrospective observational registries. Three biomarkers, including IL-8, HGF and osteopontin, satisfied Level I evidence for PFS.
Conclusion: Though several promising predictive biomarkers for VEGF-targeted therapy have been found, none of them has satisfied the determination of Level I evidence. A more focused development of biomarkers with prospective assessment in clinical trials and clear intent of use in clinical practice is needed.
Keywords: Biomarkers; Metastatic renal cell carcinoma; Systematic review; Vascular endothelial growth factor-targeted therapy.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Similar articles
- Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms.
van der Mijn JC, Mier JW, Broxterman HJ, Verheul HM. van der Mijn JC, et al. Drug Resist Updat. 2014 Oct-Dec;17(4-6):77-88. doi: 10.1016/j.drup.2014.10.003. Epub 2014 Oct 7. Drug Resist Updat. 2014. PMID: 25457974 Review. - Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. Tran HT, et al. Lancet Oncol. 2012 Aug;13(8):827-37. doi: 10.1016/S1470-2045(12)70241-3. Epub 2012 Jul 2. Lancet Oncol. 2012. PMID: 22759480 - Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.
Winer AG, Motzer RJ, Hakimi AA. Winer AG, et al. Urol Clin North Am. 2016 Feb;43(1):95-104. doi: 10.1016/j.ucl.2015.08.009. Epub 2015 Oct 31. Urol Clin North Am. 2016. PMID: 26614032 Free PMC article. Review. - Molecular biomarkers in advanced renal cell carcinoma.
Maroto P, Rini B. Maroto P, et al. Clin Cancer Res. 2014 Apr 15;20(8):2060-71. doi: 10.1158/1078-0432.CCR-13-1351. Epub 2014 Feb 13. Clin Cancer Res. 2014. PMID: 24526734 Review.
Cited by
- Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.
Hsieh JJ, Manley BJ, Khan N, Gao J, Carlo MI, Cheng EH. Hsieh JJ, et al. Semin Cell Dev Biol. 2017 Apr;64:98-106. doi: 10.1016/j.semcdb.2016.09.002. Epub 2016 Sep 8. Semin Cell Dev Biol. 2017. PMID: 27615548 Free PMC article. Review. - Renal cell carcinoma.
Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Hsieh JJ, et al. Nat Rev Dis Primers. 2017 Mar 9;3:17009. doi: 10.1038/nrdp.2017.9. Nat Rev Dis Primers. 2017. PMID: 28276433 Free PMC article. Review. - Transcriptome Sequencing (RNAseq) Enables Utilization of Formalin-Fixed, Paraffin-Embedded Biopsies with Clear Cell Renal Cell Carcinoma for Exploration of Disease Biology and Biomarker Development.
Eikrem O, Beisland C, Hjelle K, Flatberg A, Scherer A, Landolt L, Skogstrand T, Leh S, Beisvag V, Marti HP. Eikrem O, et al. PLoS One. 2016 Feb 22;11(2):e0149743. doi: 10.1371/journal.pone.0149743. eCollection 2016. PLoS One. 2016. PMID: 26901863 Free PMC article. - Expression of vascular endothelial growth factor C in renal cell carcinoma and its correlation with pathological parameters and prognosis.
Shi L, Lv R, Li C, Han D, Ren Z, Ren G. Shi L, et al. Transl Androl Urol. 2020 Aug;9(4):1670-1677. doi: 10.21037/tau-20-970. Transl Androl Urol. 2020. PMID: 32944528 Free PMC article. Retracted. - Construction of a Prognostic Model for KIRC and Identification of Drugs Sensitive to Therapies - A Comprehensive Biological Analysis Based on m6A-Related LncRNAs.
Xia D, Liu Q, Yan S, Bi L. Xia D, et al. Front Oncol. 2022 Jun 2;12:895315. doi: 10.3389/fonc.2022.895315. eCollection 2022. Front Oncol. 2022. PMID: 35719976 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials